Horizon Therapeutics (HZNP) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Horizon Therapeutics (HZNP) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance

February 24, 2021 7:00 AM EST

-- Record Fourth-Quarter 2020 Net Sales of $745.3 Million Increased 105 Percent; Fourth-Quarter 2020 GAAP Net Income of $190.6 Million; Adjusted EBITDA of $371.0 Million --

-- Record Full-Year 2020 Net Sales of $2.20 Billion Driven by 110 Percent Growth in the Orphan Segment; Full-Year 2020 GAAP Net Income of $389.8 Million; Adjusted EBITDA of $998.7 Million --

-- TEPEZZA® (teprotumumab-trbw) Fourth-Quarter 2020 Net Sales of $343.7 Million; Full-Year 2020 Net Sales of $820.0 Million, Significantly Exceeding Launch-Year Expectations; Driving One of the Best Rare Disease Medicine Launches in History --

-- Record KRYSTEXXA® (pegloticase injection) Fourth-Quarter 2020 Net Sales... More